Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Showing 1-25 of 60 citing articles:

Identification of 3-chymotrypsin like protease (3CLPro) inhibitors as potential anti-SARS-CoV-2 agents
Vicky Mody, Joanna Ho, Savannah Wills, et al.
Communications Biology (2021) Vol. 4, Iss. 1
Open Access | Times Cited: 219
Structural and Evolutionary Analysis Indicate That the SARS-CoV-2 Mpro Is a Challenging Target for Small-Molecule Inhibitor Design
Maria Bzówka, Karolina Mitusińska, Agata Raczyńska, et al.
International Journal of Molecular Sciences (2020) Vol. 21, Iss. 9, pp. 3099-3099
Open Access | Times Cited: 181
Virtual screening, molecular dynamics and structure–activity relationship studies to identify potent approved drugs for Covid-19 treatment
Md. Mahbubur Rahman, Titon Saha, Kazi Jahidul Islam, et al.
Journal of Biomolecular Structure and Dynamics (2020) Vol. 39, Iss. 16, pp. 6231-6241
Open Access | Times Cited: 105
Potential anti‐SARS‐CoV‐2 drug candidates identified through virtual screening of the ChEMBL database for compounds that target the main coronavirus protease
Motonori Tsuji
FEBS Open Bio (2020) Vol. 10, Iss. 6, pp. 995-1004
Open Access | Times Cited: 72
Therapeutics for COVID-19: from computation to practices—where we are, where we are heading to
Probir Kumar Ojha, Supratik Kar, Jillella Gopala Krishna, et al.
Molecular Diversity (2020) Vol. 25, Iss. 1, pp. 625-659
Open Access | Times Cited: 58
Repurposing of the approved small molecule drugs in order to inhibit SARS-CoV-2 S protein and human ACE2 interaction through virtual screening approaches
Hourieh Kalhor, Solmaz Sadeghi, Hoda Abolhasani, et al.
Journal of Biomolecular Structure and Dynamics (2020) Vol. 40, Iss. 3, pp. 1299-1315
Open Access | Times Cited: 55
A comprehensive review on pharmacologic agents, immunotherapies and supportive therapeutics for COVID-19
Khan Sharun, Ruchi Tiwari, Mohd I. Yatoo, et al.
Narra J (2022) Vol. 2, Iss. 3, pp. e92-e92
Open Access | Times Cited: 35
Aloin isoforms (A and B) selectively inhibits proteolytic and deubiquitinating activity of papain like protease (PLpro) of SARS-CoV-2 in vitro
Devin S. M. Lewis, Joanna Ho, Savannah Wills, et al.
Scientific Reports (2022) Vol. 12, Iss. 1
Open Access | Times Cited: 32
Identification of host transcriptome-guided repurposable drugs for SARS-CoV-1 infections and their validation with SARS-CoV-2 infections by using the integrated bioinformatics approaches
Fee Faysal Ahmed, Md. Selim Reza, Md. Shahin Sarker, et al.
PLoS ONE (2022) Vol. 17, Iss. 4, pp. e0266124-e0266124
Open Access | Times Cited: 29
Interaction of Drug Candidates with Various SARS-CoV-2 Receptors: An in Silico Study to Combat COVID-19
Rômulo Oliveira Barros, L. C. C. Fabio, Wildrimak S. Pereira, et al.
Journal of Proteome Research (2020) Vol. 19, Iss. 11, pp. 4567-4575
Open Access | Times Cited: 42
Bisindolylmaleimide IX: A novel anti-SARS-CoV2 agent targeting viral main protease 3CLpro demonstrated by virtual screening pipeline and in-vitro validation assays
Yash Gupta, Dawid Maciorowski, Samantha E. Zak, et al.
Methods (2021) Vol. 195, pp. 57-71
Open Access | Times Cited: 34
Combined deep learning and molecular docking simulations approach identifies potentially effective FDA approved drugs for repurposing against SARS-CoV-2
Muhammad Umer Anwaar, Farjad Adnan, Asma Abro, et al.
Computers in Biology and Medicine (2021) Vol. 141, pp. 105049-105049
Open Access | Times Cited: 29
Computational Simulations Identified Marine-Derived Natural Bioactive Compounds as Replication Inhibitors of SARS-CoV-2
Vikas Kumar, Shraddha Parate, Sanghwa Yoon, et al.
Frontiers in Microbiology (2021) Vol. 12
Open Access | Times Cited: 29
Exploration of inhibitory action of Azo imidazole derivatives against COVID-19 main protease (Mpro): A computational study
Abhijit Chhetri, Sailesh Chettri, Pranesh Rai, et al.
Journal of Molecular Structure (2020) Vol. 1224, pp. 129178-129178
Open Access | Times Cited: 28
Identification of potential antivirals against SARS-CoV-2 using virtual screening method
Mohammad Rejaur Rahman, Anik Banik, Ishtiak Malique Chowdhury, et al.
Informatics in Medicine Unlocked (2021) Vol. 23, pp. 100531-100531
Open Access | Times Cited: 25
9-aminominocycline potentiates the efficacy of EIDD-1931 and PF-332 by targeting the papain like protease enzyme of SARS-CoV-2
Kabita Pandey, Devin S. M. Lewis, Kyun Heo, et al.
Scientific Reports (2025) Vol. 15, Iss. 1
Open Access
In Silico Approach of Potential Phytochemical Inhibitor from Moringa oleifera, Cocos nucifera, Allium cepa, Psidium guajava, and Eucalyptus globulus for the treatment of COVID-19 by Molecular Docking
Ika Nur Fitriani, Wiji Utami, Adi Tiara Zikri, et al.
Research Square (Research Square) (2020)
Closed Access | Times Cited: 25
Protein reliability analysis and virtual screening of natural inhibitors for SARS-CoV-2 main protease (Mpro) through docking, molecular mechanic & dynamic, and ADMET profiling
Каріна Капуста, Supratik Kar, Jasmine T. Collins, et al.
Journal of Biomolecular Structure and Dynamics (2020) Vol. 39, Iss. 17, pp. 6810-6827
Open Access | Times Cited: 24
Structural insights on the interaction potential of natural leads against major protein targets of SARS-CoV-2: Molecular modelling, docking and dynamic simulation studies
Sinosh Skariyachan, Dharshini Gopal, Aditi G. Muddebihalkar, et al.
Computers in Biology and Medicine (2021) Vol. 132, pp. 104325-104325
Open Access | Times Cited: 23
Assessing the Potential Contribution of in Silico Studies in Discovering Drug Candidates that Interact with Various SARS-CoV-2 Receptors
Aganze Gloire-Aimé Mushebenge, Samuel Chima Ugbaja, Nonkululeko Avril Mbatha, et al.
(2023)
Open Access | Times Cited: 8
Identification of host genomic biomarkers from multiple transcriptomics datasets for diagnosis and therapies of SARS-CoV-2 infections
Bandhan Sarker, Md. Matiur Rahaman, Md. Ariful Islam, et al.
PLoS ONE (2023) Vol. 18, Iss. 3, pp. e0281981-e0281981
Open Access | Times Cited: 7
Hypothetical targets and plausible drugs of coronavirus infection caused by SARS‐CoV‐2
Faezeh Almasi, Fatemeh Mohammadipanah
Transboundary and Emerging Diseases (2020) Vol. 68, Iss. 2, pp. 318-332
Open Access | Times Cited: 19
Drug repurposing: new strategies for addressing COVID-19 outbreak
Pravin Shende, Bhakti Khanolkar, Rajesh Gaud
Expert Review of Anti-infective Therapy (2020) Vol. 19, Iss. 6, pp. 689-706
Closed Access | Times Cited: 19
Fármacos prometedores y potenciales para el tratamiento de COVID-19
Carlos Moneriz, Cristian Castro-Salguedo
Revista chilena de infectología (2020) Vol. 37, Iss. 3, pp. 205-215
Open Access | Times Cited: 17
Page 1 - Next Page

Scroll to top